Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://ncbi.nlm.nih.gov/pubmed/23167739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados